Showing 1601-1610 of 2494 results for "".
- Sight Sciences Announces Fee Schedule Establishment for TearCare Dry Eye Procedurehttps://modernod.com/news/sight-sciences-announces-fee-schedule-establishment-for-tearcare-dry-eye-procedure/2484193/Sight Sciences announced that two Medicare Administrative Contractors (MACs), Novitas Solutions and First Coast Service Options (FCSO), each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eye
- Orbis International Teams Up with the Alcon Foundation and OMEGA to Improve Eye Care in Zambiahttps://modernod.com/news/orbis-international-teams-up-with-the-alcon-foundation-and-omega-to-improve-eye-care-in-zambia/2481851/Global eye care nonprofit Orbis International is kicking off a surgical training program in Zambia&nb
- CSI Dry Eye Software Announces Ken Barbet as New Chief Executive Officerhttps://modernod.com/news/csi-dry-eye-software-announces-ken-barbet-as-new-chief-executive-officer/2482754/Earlier this week, CSI Dry Eye Software, an artificial intelligence-based platform to aid dry eye disease management, announced Ken Barbet at the company’s new Chief Executive Officer (CEO). Mr. Barbet has 30 years of executive leade
- Perry J. Sternberg Joins Sydnexis as Chief Executive Officerhttps://modernod.com/news/perry-j-sternberg-joins-sydnexis-as-chief-executive-officer/2482358/Sydnexis has announced the appointment of Perry J. Sternberg as Chief Executive Officer and a member of the Board of Directors. Mr. Sternberg is a pharma/biotech executive with more than 30 years in the industry and 15 years in eye care. Immediately prior to joining Sydnexis,
- RxSight Announces Pricing of Public Offering of Common Stockhttps://modernod.com/news/rxsight-announces-pricing-of-public-offering-of-common-stock/2481395/RxSight, maker of the RxSight Light Adjustable Lens system, announced it has priced its underwritten public offering. RxSight expects to sell 4 million shares of its common stock at a price to the public of $12.50 per share. RxSight has granted the underwriter a 30-day op
- EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer/2480678/EyePoint Pharmaceuticals announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings more than 30 years of global regulatory affairs experience across all phases of drug development, including ophthalmic and ocular conditions. Ms. Lefebvre is su
- Aura Biosciences Names Mark De Rosch, PhD, Chief Operating Officerhttps://modernod.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/Aura Biosciences announced the appointment of Mark De Rosch, PhD, as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy. Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and deve
- Avedro Launches Initial Public Offeringhttps://modernod.com/news/avedro-launches-initial-public-offering/2476317/Avedro announced that it has commenced an initial public offering of 5 million shares of common stock. The initial public offering price is currently estimated to be between $14 and $16 per share. Avedro expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 sha
- Ziemer USA Offers Femtosecond Laser Wet Labs at AAOhttps://modernod.com/news/ziemer-usa-offers-femtosecond-laser-wet-labs-at-aao/2479791/Ziemer USA will showcase the Z8 Femtosecond laser with Optical Coherence Tomography (OCT) in wet labs at this year’s American Academy of Ophthalmology meeting in Chicago, October 27-30. Attendees can sign up on the Zi
- FCI Ophthalmics Announces Availability of EzyPor Polyethylene Orbital Implanthttps://modernod.com/news/fci-ophthalmics-announces-availability-of-ezypor-polyethylene-orbital-implant/2481336/FCI Ophthalmics announced the launch of EzyPor in the United States. EzyPor is a high density polyethylene orbital implant with a patented suturing platform, indicated for enucleation, evisceration, and secondary implantation. Ezyor is designed to have a smooth